Introduction: Interstitial lung disease (ILD) is a progressive pulmonary disease, and many patients with ILD eventually require long-term oxygen therapy (LTOT) despite intensive treatment. Patients with ILD undergoing LTOT are usually in an advanced stage. It is clinically important to predict the prognosis of patients whose prognosis is potentially poor. However, the prognosis of patients with ILD undergoing LTOT remains unclear. Recently, serum C-reactive protein (CRP) has been reported to be associated with mortality in patients with ILD. The aim of this study was to evaluate the utility of CRP in predicting the prognosis of patients with ILD undergoing LTOT. Methods: We enrolled 101 patients with ILD undergoing LTOT at our hospital between January 2014 and December 2020. We categorized the patients based on their CRP levels and compared their median overall survival (OS). A Cox regression analysis was employed to determine the relationship between CRP levels and prognosis. Results: The number of patients categorized into Group A (CRP < 5 mg/L) and Group B (CRP ≥ 5 mg/L) was 42 and 59, respectively. The median OS of Group B was significantly shorter than that of Group A (7.66 months [95% CI: 4.24 - 13.0] vs. 20.4 months [95% CI: 9.63 - 28.8]; HR: 1.98; 95% CI: 1.24 - 3.19; p < 0.01). Multivariate Cox proportional hazards analysis demonstrated an independent association between CRP levels and OS (HR: 1.43; 95% CI: 1.12 - 1.83; p < 0.01). Conclusion: CRP is a promising tool for predicting the prognosis of patients with ILD undergoing LTOT.
References
[1]
Richeldi, L., Cottin, V., du Bois, R.M., Selman, M., Kimura, T., Bailes, Z., et al. (2016) Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Combined Evidence from the TOMORROW and INPULSIS® Trials. Respiratory Medicine, 113, 74-79. https://doi.org/10.1016/j.rmed.2016.02.001
[2]
Collard, H.R., Ryerson, C.J., Corte, T.J., Jenkins, G., Kondoh, Y., Lederer, D.J., et al. (2016) Acute Exacerbation of Idiopathic Pulmonary Fibrosis. an International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 194, 265-275. https://doi.org/10.1164/rccm.201604-0801ci
[3]
Nocturnal Oxygen Therapy Trial Group (1980) Continuous or Nocturnal Oxygen Therapy in Hypoxemic Chronic Obstructive Lung Disease. Annals of Internal Medicine, 93, 391-398. https://doi.org/10.7326/0003-4819-93-3-391
[4]
Branson, R.D. (2018) Oxygen Therapy in COPD. Respiratory Care, 63, 734-748. https://doi.org/10.4187/respcare.06312
[5]
Crockett, A., Cranston, J.M. and Antic, N. (2001) Domiciliary Oxygen for Interstitial Lung Disease. Cochrane Database of Systematic Reviews, No. 3, CD002883. https://doi.org/10.1002/14651858.cd002883
[6]
Khor, Y.H., Gutman, L., Abu Hussein, N., Johannson, K.A., Glaspole, I.N., Guler, S.A., et al. (2021) Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease. CHEST, 160, 994-1005. https://doi.org/10.1016/j.chest.2021.04.037
[7]
Lee, S.H., Shim, H.S., Cho. S.H., Kim, S.Y., Lee, S.K., Son, J.Y., et al. (2011) Prog-Nostic Factors for Idiopathic Pulmonary Fibrosis: Clinical, Physiologic, Pathologic, and Molecular Aspects. Sarcoidosis, Vasculitis and Diffuse Lung Diseases, 28, 102-112.
[8]
Chiu, Y., Spierings, J., de Jong, P.A., Hoesein, F.M., Grutters, J.C., van Laar, J.M., et al. (2021) Predictors for Progressive Fibrosis in Patients with Connective Tissue Disease Associated Interstitial Lung Diseases. Respiratory Medicine, 187, Article 106579. https://doi.org/10.1016/j.rmed.2021.106579
[9]
Stock, C.J.W., Bray, W.G., Kouranos, V., Jacob, J., Kokosi, M., George, P.M., et al. (2023) Serum C‐Reactive Protein Is Associated with Earlier Mortality across Different Interstitial Lung Diseases. Respirology, 29, 228-234. https://doi.org/10.1111/resp.14609
[10]
Rochemonteix, B.G., Wiktorowicz, K., Kushner, I. and Dayer, J. (1993) C-Reactive Protein Increases Production of Il-1α, Il-1β, and TNF-Α, and Expression of mRNA by Human Alveolar Macrophages. Journal of Leukocyte Biology, 53, 439-445. https://doi.org/10.1002/jlb.53.4.439
[11]
Borthwick, L.A. (2016) The IL-1 Cytokine Family and Its Role in Inflammation and Fibrosis in the Lung. Seminars in Immunopathology, 38, 517-534. https://doi.org/10.1007/s00281-016-0559-z
[12]
De Almeida Chaves, S., Porel, T., Mounié, M., Alric, L., Astudillo, L., Huart, A., et al. (2021) Sine Scleroderma, Limited Cutaneous, and Diffused Cutaneous Systemic Sclerosis Survival and Predictors of Mortality. Arthritis Research & Therapy, 23, Article No. 295. https://doi.org/10.1186/s13075-021-02672-y
[13]
Schulz, S., Lüdike, H., Lierath, M., Schlitt, A., Werdan, K., Hofmann, B., et al. (2016) C-Reactive Protein Levels and Genetic Variants of CRP as Prognostic Markers for Combined Cardiovascular Endpoint (Cardiovascular Death, Death from Stroke, Myocardial Infarction, and Stroke/TIA). Cytokine, 88, 71-76. https://doi.org/10.1016/j.cyto.2016.08.021
[14]
Enright, P.L. (2003) The Six-Minute Walk Test. Respiratory Care, 48, 783-785.
[15]
Ley, B., Ryerson, C.J., Vittinghoff, E., Ryu, J.H., Tomassetti, S., Lee, J.S., et al. (2012) A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis. Annals of Internal Medicine, 156, 684-691. https://doi.org/10.7326/0003-4819-156-10-201205150-00004
[16]
Raghu, G., Remy-Jardin, M., Myers, J.L., Richeldi, L., Ryerson, C.J., Lederer, D.J., et al. (2018) Diagnosis of Idiopathic Pulmonary Fibrosis. an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 198, e44-e68. https://doi.org/10.1164/rccm.201807-1255st
[17]
Fischer, A., Antoniou, K.M., Brown, K.K., Cadranel, J., Corte, T.J., du Bois, R.M., et al. (2015) An Official European Respiratory Society/American Thoracic Society Research Statement: Interstitial Pneumonia with Autoimmune Features. European Respiratory Journal, 46, 976-987. https://doi.org/10.1183/13993003.00150-2015
[18]
Kono, M., Nakamura, Y., Yoshimura, K., Enomoto, Y., Oyama, Y., Hozumi, H., et al. (2016) Nonspecific Interstitial Pneumonia Preceding Diagnosis of Collagen Vascular Disease. Respiratory Medicine, 117, 40-47. https://doi.org/10.1016/j.rmed.2016.05.030
[19]
Wetterö, J., von Löhneysen, S., Cobar, F., Kristenson, M., Garvin, P. and Sjöwall, C. (2021) Pronounced Diurnal Pattern of Salivary C-Reactive Protein (CRP) with Modest Associations to Circulating CRP Levels. Frontiers in Immunology, 11, Article 607166. https://doi.org/10.3389/fimmu.2020.607166
[20]
Zhang, K., Li, A., Zhou, J., Zhang, C. and Chen, M. (2023) Genetic Association of Circulating C-Reactive Protein Levels with Idiopathic Pulmonary Fibrosis: A Two-Sample Mendelian Randomization Study. Respiratory Research, 24, Article No. 7. https://doi.org/10.1186/s12931-022-02309-x
[21]
Kunze, R. (2019) C‐Reactive Protein: From Biomarker to Trigger of Cell Death? Therapeutic Apheresis and Dialysis, 23, 494-496. https://doi.org/10.1111/1744-9987.12802
[22]
Margaritopoulos, G.A., Antoniou, K.M. and Wells, A.U. (2017) Comorbidities in Interstitial Lung Diseases. European Respiratory Review, 26, Article 160027. https://doi.org/10.1183/16000617.0027-2016
[23]
Natsuizaka, M., Chiba, H., Kuronuma, K., Otsuka, M., Kudo, K., Mori, M., et al. (2014) Epidemiologic Survey of Japanese Patients with Idiopathic Pulmonary Fibrosis and Investigation of Ethnic Differences. American Journal of Respiratory and Critical Care Medicine, 190, 773-779. https://doi.org/10.1164/rccm.201403-0566oc
[24]
Otsuka, J., Yoshizawa, S., Ikematsu, Y., Kudo, K., Osoreda, H., Ishimatsu, A., et al. (2022) Acute Exacerbation in Antineutrophil Cytoplasmic Antibody-Associated Interstitial Lung Disease: Clinical Features and Risk Factors. Respiratory Medicine, 203, Article 106992. https://doi.org/10.1016/j.rmed.2022.106992
[25]
Miyamura, T., Sakamoto, N., Kakugawa, T., Okuno, D., Yura, H., Nakashima, S., et al. (2019) Postoperative Acute Exacerbation of Interstitial Pneumonia in Pulmonary and Non-Pulmonary Surgery: A Retrospective Study. Respiratory Research, 20, Article No. 154. https://doi.org/10.1186/s12931-019-1128-5
[26]
Kikuchi, R., Takoi, H., Tsuji, T., Nagatomo, Y., Tanaka, A., Kinoshita, H., et al. (2021) Glasgow Prognostic Score Predicts Chemotherapy‐Triggered Acute Exacerbation‐Interstitial Lung Disease in Patients with Non‐Small Cell Lung Cancer. Thoracic Cancer, 12, 667-675. https://doi.org/10.1111/1759-7714.13792
[27]
Kikuchi, R., Takoi, H., Tsuji, T., Nagatomo, Y., Tanaka, A., Kinoshita, H., et al. (2021) Glasgow Prognostic Score for Prediction of Chemotherapy‐Triggered Acute Exacerbation Interstitial Lung Disease in Patients with Small Cell Lung Cancer. Thoracic Cancer, 12, 1681-1689. https://doi.org/10.1111/1759-7714.13900
[28]
Broekhuizen, R. (2005) Raised CRP Levels Mark Metabolic and Functional Impairment in Advanced COPD. Thorax, 61, 17-22. https://doi.org/10.1136/thx.2005.041996
[29]
Agustí, A., Edwards, L.D., Rennard, S.I., MacNee, W., Tal-Singer, R., Miller, B.E., et al. (2012) Persistent Systemic Inflammation Is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLOS ONE, 7, e37483. https://doi.org/10.1371/journal.pone.0037483
[30]
She, Y.X., Yu, Q.Y. and Tang, X.X. (2021) Role of Interleukins in the Pathogenesis of Pulmonary Fibrosis. Cell Death Discovery, 7, Article No. 52. https://doi.org/10.1038/s41420-021-00437-9
[31]
Cottin, V., Hirani, N.A., Hotchkin, D.L., Nambiar, A.M., Ogura, T., Otaola, M., et al. (2018) Presentation, Diagnosis and Clinical Course of the Spectrum of Progressive-Fibrosing Interstitial Lung Diseases. European Respiratory Review, 27, Article 180076. https://doi.org/10.1183/16000617.0076-2018
Lee, S.H., Kim, S.Y., Kim, D.S., Kim, Y.W., Chung, M.P., Uh, S.T., et al. (2016) Predicting Survival of Patients with Idiopathic Pulmonary Fibrosis Using GAP Score: A Nationwide Cohort Study. Respiratory Research, 17, Article No. 131. https://doi.org/10.1186/s12931-016-0454-0
[34]
Kim, E.S., Choi, S.M., Lee, J., Park, Y.S., Lee, C., Yim, J., et al. (2015) Validation of the GAP Score in Korean Patients with Idiopathic Pulmonary Fibrosis. Chest, 147, 430-437. https://doi.org/10.1378/chest.14-0453
[35]
Tseng, C., Wang, K., Fu, P., Huang, C., Hsieh, T., Hsieh, C., et al. (2021) GAP Score and CA-153 Associated with One-Year Mortality in Anti-MDA-5 Antibody-Positive Patients: A Real-World Experience. Journal of Clinical Medicine, 10, Article 5241. https://doi.org/10.3390/jcm10225241
